Loading clinical trials...

BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH | Clinical Trials | Clareo Health

COMPLETED

BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH

Bone Mineral Density Alterations and Correlations With Bone and Muscle Metabolism Parameters During Menstrual Cessation Due to GnRH Therapy and After Menstrual Restoration

NCT04203212•424 General Military Hospital

View on ClinicalTrials.gov

Summary

The investigators aim to investigate the effect of menstrual cessation in women with endometriosis treated with GnRH analogs for 6 months on bone mineral density and bone and muscle metabolism parameters and subsequently the effects of menstrual restoration after GnRH analogs discontinuation on the above measured parameters

Detailed Description

Prospective, open-label, controlled 12month observational study Premenopausal women with surgically verified endometriosis will receive goserelin 1 injection per month for 6 months. Subsequently goserelin will be discontinued and patients will be monitored for another 6 months after menstrual restoration. Age- and BMI-matched premenopausal, health women will serve as controls. Controls will receive no treatment.

Eligibility

Age

18 - 45 years

Sex

FEMALE

Healthy Volunteers

Yes

Inclusion Criteria

•Premenopausal women with surgically verified endometriosis

Exclusion Criteria

•1. Secondary osteoporosis
•2. diseases or conditions that could affect bone and/or muscle metabolism
•3. any medications that could affect bone and/or muscle metabolism

Locations (1)

424 General Military Hospital

Thessaloniki, Greece

Key Dates

Start Date

October 1, 2019

Primary Completion Date

December 1, 2020

Completion Date

December 31, 2020

Last Updated

January 12, 2021

Enrollment

ACTUAL participants

Conditions

EndometriosisBone DensityMuscleBone Metabolism

Interventions

Goserelin Acetate

DRUG

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

NCT07061964

Muscle Invasive Bladder Urothelial CarcinomaStage II Bladder Cancer AJCC v8+1 more

View study

RECRUITINGNA

Different Drop Height Plyometric Training in Soccer Players

NCT07484425

Athletic PerformanceMuscle Strength

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 12, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

BMD Alterations and Bone and Muscle Parameters During Menstrual Cessation With GnRH

Inclusion Criteria

Exclusion Criteria

Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial

Different Drop Height Plyometric Training in Soccer Players

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study

Comparison of Rehabilitation Exercise Protocol (5R) and Swiss Ball Training for Postpartum Pelvic Floor Muscle Dysfunction

Mandibular Stretching and 4-4-8 Breathing Exercises on Autonomic Nervous System Activity

Targeting Aging With a Ketone Ester for Function in Frailty